
-
PTC Therapeutics NASDAQ:PTCT PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.
Location: 100 Corporate Ct, New Jersey, 07080-2400, US | Website: www.ptcbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.368B
Cash
1.023B
Avg Qtr Burn
-44.49M
Short % of Float
6.76%
Insider Ownership
2.58%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Emflaza (deflazacort) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
KEBILIDI™ (eladocagene exuparvovec) Details Aromatic L-amino acid decarboxylase deficiency | Approved Quarterly sales | |
Evrysdi (riskiplam) Details Spinal muscular atrophy | Approved Quarterly sales | |
Translarna (ataluren) Details Duchenne muscular dystrophy | PDUFA Approval decision | |
Sepiapterin (PTC923) Details Phenylketonuria | PDUFA Approval decision | |
Vatiquinone (PTC743) Details Friedreich’s Ataxia | NDA Acceptance for review | |
PTC518 Details Huntington's disease | Phase 2 Data readout | |
Utreloxastat Details Amyotrophic lateral sclerosis | Failed Discontinued | |
Vatiquinone (PTC743) Details Epilepsy, Mitochondrial disease | Failed Discontinued | |
PTC299 (DHODH inhibitor) Details COVID-19 | Failed Discontinued |